5-Aminosalicylic Acid
产品说明书
 |
同义名 : | 5-氨基-2-羟基苯甲酸 ;Mesalamine;5-ASA;MAX-002;AJG-501;Z-206;Asacol;Mesalazine |
| CAS号 : | 89-57-6 | |
| 货号 : | A105320 | |
| 分子式 : | C7H7NO3 | |
| 纯度 : | 98% | |
| 分子量 : | 153.135 | |
| MDL号 : | - | |
| 存储条件： |
Pure form Keep in dark place,Inert atmosphere,Room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 65 mg/mL(424.46 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | F-5-Aminosalicylic acid (5-ASA) is a specific agonist for PPARγ, and only PPARγ but not PPARα or PPARδ induces p65 degradation. 5-Aminosalicylic acid induces degradation of p65 protein indicative of PPARγ's E3 ubiquitin ligase activity. 5-Aminosalicylic acid blocks NF-κB in intestinal epithelial cells (IECs) through inhibition of PAK1[3]. Pretreatment with 5-Aminosalicylic acid (5-ASA) or Nimesulide at different concentration (10-1000 μmol/L) for 12-96 h, inhibits the growth of HT-29 colon carcinoma cells in a dose and time-dependent manner. Combined 5-Aminosalicylic acid (final concentration 100 μM) and Nimesulide (final concentration 10-1000 μM) inhibits the proliferation of HT-29 colon carcinoma cells in a dose-dependent manner, being more potent than corresponding dose of Nimesulide. In A/JOlaHsd mice, 5-ASA suppressed colon carcinogenesis by decreasing the number of aberrant crypt foci (75%) and aberrant crypts (22%) induced by AOM (azoxymethane) treatment with an absence of 5-ASA response after GW9662 administration[4]. Pretreatment with 5-ASA or nimesulide at the concentration of 10-1000 micromol/L inhibited proliferation of HT-29 colon carcinoma cells in a dose-dependent manner in vitro. The inhibition rate of HT-29 colon carcinoma cell proliferation was also increased when pretreated with 5-ASA (100 micromol/L) or nimesulide (100 micromol/L) for 12-96 h, which showed an obvious time-effect relationship. 5-ASA and nimesulide may inhibit the proliferation of HT-29 colon carcinoma cells and coadministration of these agents may have additional chemopreventive potential[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00746447 | Colitis, Ulcerative ... 展开 >> Recurrence 收起 << | Phase 3 | Completed | - | Germany ... 展开 >> Evangelisches Krankenhaus Kalk, Medical Dept. Cologne, Germany, 51103 收起 << |
| NCT01699438 | Irritable Bowel Syndrome | Phase 2 | Completed | - | Sweden ... 展开 >> Sahlgrenska University Hospital Göteborg, Sweden Karolinska University Hospital Huddinge, Sweden Norrland's University Hospital Umeå, Sweden 收起 << |
| NCT01257399 | Ulcerative Colitis in Remissio... 展开 >>n 收起 << | Phase 3 | Completed | - | China ... 展开 >> Shanghai Hospital Shanghai, China 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
6.53mL 1.31mL 0.65mL |
32.65mL 6.53mL 3.27mL |
65.30mL 13.06mL 6.53mL |
| 参考文献 |
|---|